Skip to main content
Top
Published in: Familial Cancer 4/2011

01-12-2011

The identification and management of hereditary diffuse gastric cancer in a large Jordanian family

Authors: Henry T. Lynch, Ibrahim Aldoss, Jane F. Lynch

Published in: Familial Cancer | Issue 4/2011

Login to get access

Abstract

The management of families with hereditary diffuse gastric cancer is challenging as screening for cancer in CDH1 mutation carriers is insufficiently sensitive and the commonly recommended option, prophylactic total gastrectomy, is associated with certain morbidity and even potential mortality. We describe the particular challenges associated with the diagnosis and management of a large Jordanian family with hereditary diffuse gastric cancer. A preliminary pedigree enabled DNA testing for CDH1 mutation, denoted as c.1137G → A, on 4 family members; all were identified as mutation carriers. A family information service was then conducted in Amman, Jordan, where 40 family members gathered and we provided education and counseling. Signed permission enabled DNA collection for CDH1 germline mutation studies. Non-attendees were contacted and provided detailed information. Twenty-three family members have been tested for CDH1; 13 were positive and 10 were negative. The proband, a CDH1 mutation carrier, has undergone successful prophylactic total gastrectomy. We are hopeful that this model can be repeated throughout Jordan as well as other emerging countries where knowledge and action about hereditary cancer is lacking.
Literature
2.
3.
go back to reference Alberts SR, Cervantes A, van De Velde CJ (2003) Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 14(Suppl 2):ii31–ii36 Alberts SR, Cervantes A, van De Velde CJ (2003) Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 14(Suppl 2):ii31–ii36
4.
go back to reference Lauren P (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64:31–49PubMed Lauren P (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64:31–49PubMed
5.
go back to reference Jones EG (1964) Familial gastric cancer. NZ Med J 63:287–296 Jones EG (1964) Familial gastric cancer. NZ Med J 63:287–296
6.
go back to reference Guilford P, Hopkins J, Harraway J et al (1998) E-cadherin germline mutations in familial gastric cancer. Nature 392:402–405PubMedCrossRef Guilford P, Hopkins J, Harraway J et al (1998) E-cadherin germline mutations in familial gastric cancer. Nature 392:402–405PubMedCrossRef
7.
go back to reference Kaurah P, MacMillan A, Boyd N et al (2007) Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 297:2360–2372PubMedCrossRef Kaurah P, MacMillan A, Boyd N et al (2007) Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 297:2360–2372PubMedCrossRef
8.
go back to reference Oliveira C, Senz J, Kaurah P et al (2009) Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum Mol Genet 18:1545–1555PubMedCrossRef Oliveira C, Senz J, Kaurah P et al (2009) Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum Mol Genet 18:1545–1555PubMedCrossRef
9.
go back to reference Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16:2678–2681PubMedCrossRef Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16:2678–2681PubMedCrossRef
10.
go back to reference Keller G, Vogelsang H, Becker I et al (1999) Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol 155:337–342PubMedCrossRef Keller G, Vogelsang H, Becker I et al (1999) Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol 155:337–342PubMedCrossRef
11.
go back to reference Schrader KA, Masciari S, Boyd N et al (2006) Hereditary diffuse gastric cancer: association with lobular breast cancer. Fam Cancer 7:73–82CrossRef Schrader KA, Masciari S, Boyd N et al (2006) Hereditary diffuse gastric cancer: association with lobular breast cancer. Fam Cancer 7:73–82CrossRef
12.
go back to reference Fitzgerald RC, Hardwick R, Huntsman D et al (2010) Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 47:436–444PubMedCrossRef Fitzgerald RC, Hardwick R, Huntsman D et al (2010) Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 47:436–444PubMedCrossRef
13.
go back to reference Caldas C, Carneiro F, Lynch HT et al (1999) Familial gastric cancer: overview and guidelines for management. J Med Genet 36:873–880PubMed Caldas C, Carneiro F, Lynch HT et al (1999) Familial gastric cancer: overview and guidelines for management. J Med Genet 36:873–880PubMed
14.
go back to reference Huntsman DG, Carneiro F, Lewis FR et al (2001) Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 344:1904–1909PubMedCrossRef Huntsman DG, Carneiro F, Lewis FR et al (2001) Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 344:1904–1909PubMedCrossRef
15.
go back to reference Pedrazzani C, Corso G, Marrelli D et al (2007) E-cadherin and hereditary diffuse gastric cancer. Surgery 142:645–657PubMedCrossRef Pedrazzani C, Corso G, Marrelli D et al (2007) E-cadherin and hereditary diffuse gastric cancer. Surgery 142:645–657PubMedCrossRef
17.
go back to reference Suriano G, Seixas S, Rocha J et al (2006) A model to infer the pathogenic significance of CDH1 germline missense variants. J Mol Med 84:1023–1031PubMedCrossRef Suriano G, Seixas S, Rocha J et al (2006) A model to infer the pathogenic significance of CDH1 germline missense variants. J Mol Med 84:1023–1031PubMedCrossRef
18.
go back to reference Yoon SS (2011) How closely should we follow gastric cancer patients following surgical resection? Ann Surg Oncol 18:311–313PubMedCrossRef Yoon SS (2011) How closely should we follow gastric cancer patients following surgical resection? Ann Surg Oncol 18:311–313PubMedCrossRef
19.
go back to reference Carneiro F, Huntsman DG, Smyrk TC et al (2004) Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol 203:681–687PubMedCrossRef Carneiro F, Huntsman DG, Smyrk TC et al (2004) Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol 203:681–687PubMedCrossRef
20.
go back to reference Mayrbaeurl B, Keller G, Schauer W et al (2010) Germline mutation of the E-cadherin gene in three sibling cases with advanced gastric cancer: clinical consequences for the other family members. Eur J Gastroenterol Hepatol 22:306–310PubMedCrossRef Mayrbaeurl B, Keller G, Schauer W et al (2010) Germline mutation of the E-cadherin gene in three sibling cases with advanced gastric cancer: clinical consequences for the other family members. Eur J Gastroenterol Hepatol 22:306–310PubMedCrossRef
21.
go back to reference Lynch HT, Silva E, Wirtzfeld D et al (2008) Hereditary diffuse gastric cancer: prophylactic surgical oncology implications. Surg Clin N Am 88:759–778PubMedCrossRef Lynch HT, Silva E, Wirtzfeld D et al (2008) Hereditary diffuse gastric cancer: prophylactic surgical oncology implications. Surg Clin N Am 88:759–778PubMedCrossRef
22.
go back to reference Lynch HT, Kaurah P, Wirtzfeld D et al (2008) Hereditary diffuse gastric cancer: diagnosis, genetic counseling, and prophylactic total gastrectomy. Cancer 112:2655–2663PubMedCrossRef Lynch HT, Kaurah P, Wirtzfeld D et al (2008) Hereditary diffuse gastric cancer: diagnosis, genetic counseling, and prophylactic total gastrectomy. Cancer 112:2655–2663PubMedCrossRef
23.
go back to reference Lynch HT, Grady W, Suriano G, Huntsman D (2005) Gastric cancer: new genetic developments. J Surg Oncol 90:114–133PubMedCrossRef Lynch HT, Grady W, Suriano G, Huntsman D (2005) Gastric cancer: new genetic developments. J Surg Oncol 90:114–133PubMedCrossRef
24.
go back to reference Mullins F, Dietz L, Lay M et al (2007) Identification of an intronic single nucleotide polymorphism leading to allele dropout during validation of a CDH1 sequencing assay: implications for designing polymerase chain reaction-based assays. Genet Med 9:752–760PubMedCrossRef Mullins F, Dietz L, Lay M et al (2007) Identification of an intronic single nucleotide polymorphism leading to allele dropout during validation of a CDH1 sequencing assay: implications for designing polymerase chain reaction-based assays. Genet Med 9:752–760PubMedCrossRef
26.
go back to reference Alwan A, Modell B (2003) Recommendations for introducing genetics services in developing countries. Nat Rev Genet 4:61–68PubMedCrossRef Alwan A, Modell B (2003) Recommendations for introducing genetics services in developing countries. Nat Rev Genet 4:61–68PubMedCrossRef
Metadata
Title
The identification and management of hereditary diffuse gastric cancer in a large Jordanian family
Authors
Henry T. Lynch
Ibrahim Aldoss
Jane F. Lynch
Publication date
01-12-2011
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 4/2011
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-011-9463-9

Other articles of this Issue 4/2011

Familial Cancer 4/2011 Go to the issue

Abstract

Abstracts

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine